Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-treated Lacticaseibacillus paracasei PS23
- Development stage
- Unknown
- Lead developer
- Bened Biomedical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Heat-treated *Lacticaseibacillus paracasei* PS23 (HT-PS23) is a postbiotic consisting of heat-killed bacterial cells of the PS23 strain. Developed by Bened Biomedical (Bened Life), it is designed to modulate the gut-brain axis. Clinical research indicates its potential in reducing anxiety and stress, improving sleep quality, and enhancing cognitive function and muscle strength, particularly in elderly populations. Its mechanism of action involves the modulation of neurotransmitters like dopamine, reduction of stress hormones such as cortisol, and regulation of inflammatory cytokines (IL-6, TNF-α, CRP) and brain-derived neurotrophic factor (BDNF). It is commercially available as a dietary supplement under the brand name Neuralli Mood.
- Brand names
- Neuralli Mood
- Other names
- heat-killed Lacticaseibacillus paracasei PS23heat-inactivated Lacticaseibacillus paracasei PS23L. paracasei PS23 postbiotic
02
Targets
IL-6 (Interleukin 6)BDNF (Brain-derived neurotrophic factor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on heat-treated Lacticaseibacillus paracasei PS23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-treated Lacticaseibacillus paracasei PS23.